Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains.

Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther MA, Iorio A.

Haemophilia. 2018 Dec 6. doi: 10.1111/hae.13649. [Epub ahead of print]

PMID:
30520534
2.

Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls.

Mannucci PM, Nobili A, Marchesini E, Oliovecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Peyvandi F, Iorio A.

Haemophilia. 2018 Sep;24(5):726-732. doi: 10.1111/hae.13595. Epub 2018 Aug 16.

PMID:
30112863
3.

Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire.

Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther M, Iorio A.

BMJ Open. 2018 Aug 8;8(8):e021900. doi: 10.1136/bmjopen-2018-021900.

4.

Focusing in on use of pharmacokinetic profiles in routine hemophilia care.

Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A.

Res Pract Thromb Haemost. 2018 May 27;2(3):607-614. doi: 10.1002/rth2.12118. eCollection 2018 Jul.

5.

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.

Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE, Fischer K, Hart DP, Ito S, Korth-Bradley J, Lethagen S, Lillicrap D, Makris M, Mathôt R, Morfini M, Neufeld EJ, Spears J.

Res Pract Thromb Haemost. 2018 May 20;2(3):535-548. doi: 10.1002/rth2.12106. eCollection 2018 Jul. Review.

6.

Using pharmacokinetics to individualize hemophilia therapy.

Iorio A.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):595-604. doi: 10.1182/asheducation-2017.1.595. Review.

7.

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis.

McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton AN.

Pharmaceutics. 2017 Oct 17;9(4). pii: E47. doi: 10.3390/pharmaceutics9040047.

8.

Thrombosis in Inherited Fibrinogen Disorders.

Korte W, Poon MC, Iorio A, Makris M.

Transfus Med Hemother. 2017 Apr;44(2):70-76. doi: 10.1159/000452864. Epub 2017 Mar 14. Review.

9.

Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.

Iorio A, Fischer K, Makris M.

Br J Haematol. 2017 Jul;178(1):20-31. doi: 10.1111/bjh.14610. Epub 2017 Apr 7. Review.

10.

Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.

Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG).

Thromb Haemost. 2017 Jun 2;117(6):1023-1030. doi: 10.1160/TH16-12-0942. Epub 2017 Mar 30. Review.

PMID:
28357444
11.

The current state of adverse event reporting in hemophilia.

van Vulpen LF, Saccullo G, Iorio A, Makris M.

Expert Rev Hematol. 2017 Feb;10(2):161-168. doi: 10.1080/17474086.2017.1272410. Epub 2016 Dec 26. Review.

12.

Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol.

Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton AN, Thabane L; WAPPS-Hemo co-investigator network.

JMIR Res Protoc. 2016 Dec 15;5(4):e239.

14.

Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.

Iorio A, Krishnan S, Myrén KJ, Lethagen S, McCormick N, Yermakov S, Karner P.

J Med Econ. 2017 Apr;20(4):337-344. doi: 10.1080/13696998.2016.1265973. Epub 2016 Dec 21.

PMID:
27885871
15.

Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study.

James PD, Mahlangu J, Bidlingmaier C, Mingot-Castellano ME, Chitlur M, Fogarty PF, Cuker A, Mancuso ME, Holme PA, Grabell J, Satkunam N, Hopman WM, Mathew P; Global Emerging HEmostasis Experts Panel (GEHEP).

Haemophilia. 2016 Nov;22(6):912-918. doi: 10.1111/hae.13089.

PMID:
27868369
16.

Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study.

Cheng J, Iorio A, Marcucci M, Romanov V, Pullenayegum EM, Marshall JK, Thabane L.

J Blood Med. 2016 Oct 25;7:239-253. eCollection 2016.

17.

The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.

McEneny-King A, Iorio A, Foster G, Edginton AN.

Expert Opin Drug Metab Toxicol. 2016 Aug 19:1-9. [Epub ahead of print]

PMID:
27539370
18.

Haemophilia in a real-world setting: the value of clinical experience in data collection.

Dolan G, Iorio A, Jokela V, Juusola K, Lassila R.

Eur J Haematol. 2016 Feb;96 Suppl 82:3-9. doi: 10.1111/ejh.12715.

PMID:
26809546
19.

Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.

Matino D, Makris M, Dwan K, D'Amico R, Iorio A.

Cochrane Database Syst Rev. 2015 Dec 16;(12):CD004449. doi: 10.1002/14651858.CD004449.pub4. Review.

PMID:
26677005
20.

Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study.

Palareti L, Potì S, Cassis F, Emiliani F, Matino D, Iorio A.

Int J Qual Stud Health Well-being. 2015 Nov 16;10:28915. doi: 10.3402/qhw.v10.28915. eCollection 2015.

Supplemental Content

Loading ...
Support Center